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Abstract
Background: Bladder cancer outcomes have not changed significantly in 30 years; the BladderPath trial (Image
Directed Redesign of Bladder Cancer Treatment Pathway, ISRCTN35296862) proposes to evaluate a modified
pathway for diagnosis and treatment ensuring appropriate pathways are undertaken earlier to improve outcomes.
We are piloting a novel data collection technique based on routine National Health Service (NHS) data, with no
traditional patient-Health Care Professional contact after recruitment, where trial data are traditionally collected on
case report forms. Data will be collected from routine administrative sources and validated via data queries to sites.
We report here the feasibility and pre-trial methodological development and validation of the schema proposed for
BladderPath.
Methods: Locally treated patient cohorts were utilised for routine data validation (hospital interactions data (HID)
and administrative radiotherapy department data (RTD)). Single site events of interest were algorithmically extracted
from the 2008–2018 HID and validated against reference datasets to determine detection sensitivity. Survival
analysis was performed using RTD and HID data. Hazard ratios and survival statistics were calculated estimating
treatment effects and further validating and assessing the scope of routine data.
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Results: Overall, 829/1042 (sensitivity 0.80) events of interest were identified in the HID, with varying levels of
sensitivity; identifying, 202/206 (sensitivity 0.98; PPV 0.96) surgical events but only 391/568 (sensitivity 0.69; PPV 0.95)
radiotherapy regimens. An overall temporal quality improvement trend was present: detecting 41/117 events (35%)
in 2011 to 104/109 (95%) in 2017 (all event types). Using the RTD, 5-year survival rates were 43% (95% CI 25–59%)
in the chemoradiotherapy group and 30% (95% CI 23–36%) in the radiotherapy group; using the HID, the 5-year
radical cystectomy survival rate was 57% (95% CI 50–63%).
Conclusions: Routine data are a feasible method for trial data collection. As long as events of interest are pre-
validated, very high sensitivities for trial conduct can be achieved and further improved with targeted data queries.
Outcomes can also be produced comparable to clinical trial and national dataset results. Given the real-time,
obligatory nature of the HID, which forms the Hospital Episode Statistics (HES) data, alongside other datasets, we
believe routine data extraction and validation is a robust way of rapidly collecting datasets for trials.
Keywords: Bladder cancer, Routine, Administrative, Data, Outcomes, Events, Follow-up, Randomised controlled trial
(RCT), BladderPath, Hospital episode statistics (HES)
Background
Outcomes for Bladder cancer have not changed signifi-
cantly for decades. We hypothesise one reason for this is
the delay from diagnosis to the correct treatment. The
BladderPath trial (ISRCTN35296862) is assessing a rede-
signed pathway, replacing transurethral resection of
bladder tumour (TURBT) with initial magnetic reson-
ance imaging (MRI), with the purpose of fast-tracking
patients with muscle invasive bladder cancer (MIBC)
directly to the correct treatment [1].
In order to achieve broad recruitment with minimal
clinical disruption, the trial also aims to use routine ad-
ministrative data as the basis for follow-up. We believe
that no interventional randomised controlled trial (RCT)
has been conducted in an oncology setting in the UK,
using routine data sources as a replacement for conven-
tionally collected follow-up data.
Traditionally, upon entering a trial, data are collected
during patient follow-up visits, via patient-clinician con-
tact and case report forms (CRF) are completed manually.
However, our proposed method of follow-up proceeds as
shown in Fig. 1. Upon entering the trial, participant con-
sent to access routine National Health Service (NHS)
datasets (for example, Hospital Episode Statistics (HES)
[2], the national radiotherapy data set (RTDS) [3] and the
systemic anti-cancer therapy data set (SACT) [4]) is being
obtained. These data records will be processed regularly
to identify events of interest. These events will be collated
into pre-populated electronic CRFs and sent to sites for
verification of accuracy and completeness. The completed
record will then be uploaded into the trial database.
Here, we outline a study assessing the feasibility of this
proposed methodology, utilising routine data, for clinical
trial follow-up within the BladderPath trial.
Specific feasibility objectives to be addressed include
(1) assessing the scope of using routine data solely for
RCT follow-up—for example, assessing, data quality, the
availability of key variables, datasets required, routine
data utility, data timeliness, regulatory requirements and
designing an algorithm for data extraction. Routine data
quality and utility are analysed directly by comparison to
reference data sets and indirectly, through performing
survival analyses; (2) If this data is deemed appropriate,
design a framework for use in an RCT.
Methods
Data sources
The BladderPath trial proposes to use HES [2] and
RTDS [3] for data collection, therefore, the local Hos-
pital Interaction Data (HID) (returned centrally to form
the HES) and RTD (local administrative linear acceler-
ator (LINAC) machine prescription radiotherapy data
with similarity to the RTDS) were used as equivalents.
Hence, five unique data sources were accessed within
the University Hospitals Birmingham Queen Elizabeth
Hospital (UHB QEH: BladderPath lead site); (1) RTD
(reference cohort identified using the International
Classification of Diseases (ICD) ICD-10 [5] bladder
cancer code C67X), (2) manually collated surgical data
(used for surgical cohort identification), (3) HID (in-
patient and outpatient service interactions) [6], extracted
using NHS number and local hospital unit number
Fig. 1 Proposed data flow for the BladderPath trial
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identified in the reference cohorts. The cystectomy co-
hort HID were extracted for events one-year prior to
cystectomy date in the manually collected surgical refer-
ence and censored at 31 March 2018. The radiotherapy
cohort HID were extracted from first radiotherapy event
in the RTD reference, 01 January 2011 and censored at
31 May 2018, (4) clinical note review data and (5) NHS
Spine data [7] for date of death. In addition, the national
dataset from the British Association of Urological Sur-
geons (BAUS) [8], was accessed to enhance the surgical
reference data where required [9]. During the validation
process, these five data sources were utilised as two data
types, reference (to validate) and test (to be validated)
(Table 1).
Reference data
Reference data consisted of three sources: (1) manually
collated surgical data (to validate surgical HID events),
(2) RTD (to validate radiotherapy HID events) and (3)
clinical note review data (to validate the following HID
events: chemotherapy, cystoscopy, Bacillus Calmette-
Guérin (BCG) and censor (last follow-up) (Table 1). The
data analysts had extensive experience of the reference
extraction processes and datasets and clinical guidance
was sought (via NJ, PP and AD) where required. These
were deemed suitable reference datasets due to the
method of generation; the surgical and clinical note re-
view data were collated manually by healthcare profes-
sionals and the RTD data are collected directly from
radiotherapy treatment machines, upon radiotherapy
administration.
Test data
Test data consisted of two sources: HID and RTD. The
RTD was used as a reference for HID quality validation
but during survival analysis was also used as a test
dataset alongside the HID and NHS Spine data records.
Therefore, the RTD were used as both a reference and a
test dataset (Table 1).
Patient cohorts
Data quality was established using various cohorts, in-
cluding 206 patients undergoing cystectomy (bladder re-
moval) surgery (not exclusively for bladder cancer)
between 08 January 2010 and 07 April 2017. Random
HID identified subsets were further used to evaluate
occurrences of events of interest: chemotherapy (40
patients, 47 regimen events), cystoscopy pre and post
cystectomy (29 patients, 106 events), BCG (30 patients,
114 events, 15 regimen events) and last follow-up censor
event (related patient visit to hospital, see Additional file
1: 100 patients, 100 events). During survival validation,
335 patients undergoing radical cystectomy were evalu-
ated, treated between 01 January 2011 and 07 April 2017
(132/335 surgical events involved in data quality assess-
ment above and 203/335 novel events, including patients
from other sites within UHB. The remaining 74/206 pa-
tients used in the data quality assessment were excluded
due to: 4 not coded for cystectomy, 18 partial cystecto-
mies, 14 prior to 01 January 2011 and 38 performed for
non-bladder cancer purposes). The patients were identi-
fied from the HID data using OPCS-4 [10] cystectomy
codes (Additional file 1). ICD-10 (C67 bladder cancer
and D090 bladder cancer in situ) codes were used to
identify bladder cancer where case note review reference
was not possible (e.g. for non-UHB QEH).
In addition, 525 bladder cancer patients were identi-
fied from the RTD (radical and palliative), treated be-
tween 01 January 2011 and 11 June 2018, of which 524
had at least one HID event. 336/525 of the patients, who
were undergoing radical radiotherapy (identified by the
LINAC defined intention to treat) were further evaluated
with respect to survival outcomes. For data quality valid-
ation, a total of 707 patients had at least one event of
interest validated.
Processing and outcome measures
An algorithm was written in R [11] using R Studio [12]
to extract events of interest from the routine HID.
Events of interest: surgery to bladder to remove tumour
Table 1 The reference and test datasets analysed
Data type Dataset Purpose Extracted from How cohort extracted
Reference data Surgical data -Identify cohort
-Validate HID
Data quality analyses:




Clinical note review data -Validate HID Manually
RTD (radiotherapy data) -Identify cohort
-Validate HID
By ICD-10 code






(during data quality and
survival analysesa)
By NHS and hospital numbers
(from reference)
a NHS spine data was used in addition to enable survival analyses calculation
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(cystectomy, cystoprostatectomy, exenteration), radio-
therapy (radical, palliative), cystoscopy (all cystoscopies,
including but not limited to flexible (cystoscopy or
urethroscopy) or rigid TURBT), BCG therapy, chemo-
therapy (any cancer) and last known interaction with ur-
ology or oncology services (inpatient or outpatient event
censor).All procedures were identified using Classifica-
tion of Interventions and Procedures (OPCS) version
4.4–4.8 (10) and censor date validated from the NHS
Digital main speciality coding [13] (Additional file 1).
For survival analysis, algorithms were written using the
Microsoft SQL server; for radical radiotherapy outcomes,
synchronous chemotherapy events were extracted from
the HID (Additional file 1, code present 4 weeks ± radio-
therapy initiation) and linked to the RTD and NHS
Spine data sets. For radical cystectomy outcomes, the
cystectomy-type procedures were identified in the HID
using OPCS codes (Additional file 1). For maximum
data follow-up (90 months), survival outcome analyses
(post-01 January 2011), cystectomy participants without
a survival event were censored at the data freeze, 14 June
2018, and radiotherapy participants, 29 June 2018.
Sample size summary
Two cohorts were extracted for the analyses (radiother-
apy and surgical). Initially the cohorts were searched for
all patients receiving radical or palliative radiotherapy
for bladder cancer (525 patients), or surgery to the blad-
der (277 patients), treated at UHB between January
2011–June 2018 and January 2010–April 2017, respect-
ively. Subsets were analysed for the data quality and
survival analyses, which can be seen in detail in the
‘patient cohorts’ subsection above.
Analytical methods
The events of interest, by date, were manually compared
to the reference events, and sensitivity and positive pre-
dictive value (PPV) calculated. Concordance of exact
procedure code was not required due to the querying
technique not requiring exact identification for the
BladderPath trial. Operation dates were not available for
outpatient events (e.g. flexible cystoscopy); therefore,
date of appointment was validated. For radiotherapy,
chemotherapy and BCG events, analysis was undertaken
for regimen level accuracy, detection of only one event
was required to identify the regimen. Events were subse-
quently grouped by year to assess sensitivity over time.
Kaplan-Meier survival curves were constructed using
Stata version 15 [14] to identify 5 -year (60 months)
survival plus 95% confidence intervals (CI), comparing
chemoradiotherapy and radiotherapy alone or radical
cystectomy. Cox proportional hazards models were con-
structed for radiotherapy hazard ratio (HR) analyses with
60, 72 and 90-month follow-up. Patient characteristics
were calculated using the routine HID, including the
Charlson Comorbidity Index scores (Charlson scores)
[15] identified upon inpatient procedure (either the date
of surgery to bladder or the nearest inpatient admission
to the start date of the radiotherapy).
Results
Patient characteristics can be seen below in Table 2.
Only one patient (radiotherapy data quality cohort, pal-
liative) had no coded HID events; hence, the number of
patients included in the analysis were 524/525 (99.8%).
Data quality
Overall, 829/1042 (sensitivity 0.80) events were identified
in the HID (Additional file 2), with the individual events
by year seen in Table 3. There was an overall data qual-
ity improvement of 60.4% (2011–2017), from detecting
41/117 (2011 sensitivity 0.35) to 104/109 events (2017
sensitivity: 0.95), with a mean sensitivity of 0.97 over the
last 4 years (Additional file 3).
In the surgical cohort, 206/206 patients had at least
one inpatient or outpatient interaction identified in the
HID (sensitivity 1.00). 202/206 (sensitivity 0.98) surgical
events were identified less than 2 weeks from the refer-
ence date of procedure (delays included, two 1-day, one
4-day and one 13-day delay). Therefore, 198/206
(sensitivity 0.96) procedures were identified to the exact
date. Eight false positives were detected (PPV 0.96) due
to duplicates, unrelated and abandoned procedures. The
coding quality was consistently high with the greatest
number of missing events in 2012 (three). 44/47
(sensitivity 0.94) chemotherapy regimens were identified
with three false positives (BCG treatments) (PPV 0.94);
again the detection rate was consistently high (2010–
2017) with all events captured post-2011. 89/106
cystoscopies (sensitivity: 0.84), including 32/32 (sensitiv-
ity 1.00) TURBT and 41/53 (sensitivity: 0.77) flexible
cystoscopy events, were identified, plus six false positives
(PPV 0.94) (nephrostogram plus insertion of stent, cysto-
diathermy, three duplicate records and an extirpation of
bladder lesion). 89/100 (sensitivity 0.89) censor events
were identified, with a decrease in data quality post-2016
(in contrast to other outcomes). 114/149 (sensitivity
0.77) individual BCG administrations and 14/15 regi-
mens were identified (sensitivity: 0.93), with 20 false
positive regimens (PPV 0.41) (the majority due to
Mitomycin C administration).
In the radiotherapy cohort, 524/525 patients had at
least one inpatient or outpatient interaction in the HID
(sensitivity 1.00). 391/568 (sensitivity 0.69) of regimens
were identified, with 20 false positives (PPV 0.95). Data
quality improved by 98.6% between 2011 (sensitivity
0.01) and 2017 (sensitivity 1.00). 5121/7894 individual
fractions (sensitivity 0.65) were identified.
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The sensitivity of detecting the main correct treat-
ments (surgery, radiotherapy and chemotherapy), enab-
ling calculation of BladderPath primary outcome
measures, can be seen in Fig. 2.
Survival analysis
In the RTD analysis, 5-year survival rates (Fig. 3) were
43% (95% CI 25-59%) in the chemoradiotherapy group
compared to 30% (95% CI 23–36%) in the radiotherapy
group alone (hazard ratio, 0.57 with 6-year (72 months)
follow-up (95% CI 0.37–0.88; P = 0.01)). In the HID
cystectomy analysis, the 5-year cystectomy survival rate
was 57% (95% CI 50–63%). By comparison to published
trial and national datasets, the routine data integrity and
utility is indirectly validated and hence, further provides
evidence towards the feasibility of using the RTDS and
HES for BladderPath.
Discussion
Clinical trials have used routine data to supplement or
verify data collection for decades [16–18] and many data
validation studies have been undertaken into different
databases worldwide [19, 20]. The benefits and limita-
tions of utilising routine data for RCTs have also been
evaluated in depth [21–24] but, despite this, there is lim-
ited evidence and therefore, confidence, of using routine
data as a replacement to traditional patient-Health Care
Professional follow-up techniques within clinical trials
[25, 26]. Most RCTs involve this clinical contact to rec-
ord outcomes, which is resource, time and cost inten-
sive; we believe the use of routine data may provide an
alternative framework.
The results of this study have directly informed the
data collection techniques for the BladderPath trial. As
hypothesised, events are missed, but this is estimated to
have little impact on the data quality for the trial. As
shown, data quality is improving, with a mean sensitivity
of 97% over four later years (2014–2017). Surgical cod-
ing was of consistently high quality, contrary to the
radiotherapy coding which was low quality until 2013/
2014. This dramatic improvement in radiotherapy cod-
ing quality occurred following coding consultation, due
to the primary payment function of these administrative
data, impacting remuneration for the hospital. Due to
remuneration driving central and local initiatives, we
postulate that this increase in accuracy would occur at
other centres nationally [27]. The quality of all data
items, except censor date, reached 100% in the last full
HID data year (2017). The national data quality will be
assessed upon acquisition of these data for BladderPath;
each event of interest will be queried in the clinical not-
ing at each site. BladderPath aims to develop a feedback
Table 2 Patient characteristics for the surgical and radiotherapy cohorts
Data quality analysis cohorts Survival analysis cohorts
All radiotherapy Surgical Radical radiotherapy Radical cystectomy
n = 525 n = 206 Chemoradiation
n = 66
Radiotherapy
alone n = 270
All n = 335
Number of patients (%)
Age at 1st treatment Median (IQR) 75 (68–94) 66.5 (56–73) 75 (67–79) 76.5 (70–82) 68 (62–74)
Range 31–96 22–85 52–90 42–94 23–86
Gender Male 380 (72.4%) 147 (71.4%) 47 (71.2%) 200 (74.1%) 248 (74.0%)
Female 144 (27.4%) 59 (28.6%) 19 (28.8%) 70 (25.9%) 87 (26.0%)
Ethnicity White 401 (76.4%) 191 (92.7%) 53 (80.3%) 203 (75.2%) 304 (90.7%)
Asian/Asian British 18 (3.4%) 9 (4.4%) 2 (3.0%) 9 (3.3%) 17 (5.1%)
Black/Black British 5 (1.0%) 3 (1.5%) 0 (0.0%) 4 (1.5%) 1 (0.3%)
Mixed 7 (1.3%) 0 (0.0%) 2 (3.0%) 3 (1.1%) 1 (0.3%)
Other 2 (0.4%) 2 (1.0%) 1 (1.5%) 0 (0.0%) 2 (0.6%)
Unknown 91 (17.3%) 1 (0.5%) 8 (12.1%) 51 (18.9%) 10 (3%)
Charlson score < 1 253 (48.2%) 116 (56.3%) 33 (50.0%) 125 (46.3%) 216 (64.5%)
1–5 73 (13.9%) 45 (21.8%) 14 (21.2%) 31 (11.5%) 55 (16.4%)
6–10 39 (7.4%) 23 (11.2%) 8 (12.1%) 17 (6.3%) 45 (13.4%)
11–15 21 (4.0%) 10 (4.9%) 3 (4.5%) 7 (2.6%) 12 (3.6%)
16–20 11 (2.1%) 5 (2.4%) 4 (6.1%) 5 (1.9%) 4 (1.2%)
> 20 8 (1.5%) 3 (1.5%) 0 (0.0%) 4 (1.5%) 3 (0.9%)
Unknown 119 (22.7%) 4 (1.9%) 4 (6.1%) 81 (30.0%) 0 (0.0%)
Patients without a HID inpatient event have an unknown Charlson score. Due to rounding, percentages may not sum to 100%
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Table 3 Sensitivity of the HID coding compared to the reference events, over a 10-year period (2008–2018)
Number of
events
Year of event No. false
positives
(PPV)
2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
Cystectomy Reference NA NA 16 21 28 26 41 34 34 6 NA 8 (0.96)
Routine data (HID) NA NA 16 21 25 25 41 34 34 6 NA
Sensitivity (%) – – 100.0 100.0 89.3 96.2 100.0 100.0 100.0 100.0 -
Radiotherapy regimen Reference NA NA NA 74 83 72 67 79 93 68 32 20 (0.95)
Routine data (HID) NA NA NA 1 1 55 66 79 92 68 29
Sensitivity (%) – – – 1.4 1.2 76.4 98.5 100.0 98.9 100.0 90.6
Censor Reference NA NA 1 5 4 8 16 11 9 27 19 0 (1.00)
Routine data (HID) NA NA 1 5 4 8 16 11 9 22 13
Sensitivity (%) – – NA 100.0 100.0 100.0 100.0 100.0 100.0 81.5 68.4
BCG regimen Reference NA NA 1 3 1 4 2 3 1 NA NA 20 (0.41)
Routine data (HID) NA NA 1 3 0 4 2 3 1 NA NA
Sensitivity (%) – – NA 100.0 – 100.0 100.0 100.0 – – –
Cystoscopy Reference NA 3 8 8 21 20 15 15 9 5 2 6 (0.94)
Routine data (HID) NA 2 6 6 19 17 12 11 9 5 2
Sensitivity (%) – 66.7 75.0 75.0 90.5 85.0 80.0 73.3 100.0 100.0 100.0
Chemotherapy regimen Reference 1 1 4 6 7 9 5 7 3 3 1 3 (0.94)
Routine data (HID) 0 0 4 5 7 9 5 7 3 3 1
Sensitivity (%) – – 100.0 83.3 100.0 100.0 100.0 100.0 100.0 100.0 –
NA = no events were validated (due to the random sample selected, or due to the data censor, for example, surgery to bladder censor mid-2017). (-), if only one
event, or none were validated, the sensitivity was not calculated due to the sample size. Only six cystectomies were validated in the 2017 data due to the
reference data freeze
Fig. 2 Sensitivity of detection for the first correct treatments collected as primary outcome measures in BladderPath (surgery to bladder,
chemotherapy and radiotherapy) for HID data years 2010–2017
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mechanism to continually send this quality measure to
the data providers for service improvement, aiming to
remove the query requirement for future trials. As Blad-
derPath is designed without clinic-based follow-up, the
events cannot be validated against standard trial data,
only clinical noting.
Of note, the three missing radiotherapy events in 2018
highlights a limitation of HID/HES data - time lag in
Fig. 3 Kaplan Meier survival curves for the routine data (HID & RTD) derived data cohorts to 6 years. a Radiotherapy outcomes, showing 6-year
HR. b Cystectomy outcomes
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data access, resulting in non-identifiable events occur-
ring after the HID data censor. Until clinical systems can
produce and synchronise real-time data with routine
data providers, alongside continual automatic data clean-
ing processes, a delay will be present when acquiring rou-
tine data. This is particularly important for trials
collecting safety related events. Hence, it is possible that
some trials may not be appropriate to follow-up in this
manner. We believe, overall, this delay may be compar-
able, if not improved, to conventionally obtained trial data
(collected during predefined follow-up visits) particularly
when visits become less frequent, upon long term follow-
up. Data providers release data with different delays. Dis-
cussion is currently underway with providers to ensure
that this delay is minimal; the providers understand that
this technique is novel and are developing this process
alongside BladderPath. The feasibility of the approach will
be confirmed upon acquisition of the data.
To ensure maximum data quality, further reduce miss-
ingness and increase our confidence, we also intend to
cross-check HES events with the following additional
datasets: the National Radiotherapy dataset (RTDS) [3],
Systemic Anti-Cancer Therapy data set (SACT) [4] and
the Diagnostic Imaging Database (Table 4) [28]. Nation-
ally (within England), these data are collected to a struc-
tured schema, so events are available in the same format
across sites. Due to not having access to the national da-
tabases within this study, a restricted number of data
sources were validated here. However, additional data-
bases should increase event detection within the trial.
However, the more datasets acquired, the more re-
sources are needed to (1) apply for these data, (2) receive
these data at frequent intervals, possibly from multiple
providers (arranging transfer and for which participants),
(3) merge these data (potentially from multiple providers
with potential data updates), (4) validate these data and
(5) process these data (produce meaningful CRF data).
These steps require extensive planning, for example, for
receiving these data; during the trial there will be cohort
alterations (patients recruiting or withdrawing). Hence,
for every extract BladderPath plan to send the providers
an updated cohort list to re-run the data query.
The datasets analysed in this study were deemed suit-
able equivalents to the national datasets for BladderPath.
Where alternatives are available (local data), initially na-
tional data should not be acquired as may not be fit for
purpose. Alternatives enabled this proof-of-concept
study prior to acquiring data for BladderPath. It is
hypothesised that the HES data will exceed the HID
quality due to additional provider level processing, prior
to release.
The technique of querying all data items against a clin-
ical reference as verified in this study, during the trial,
will also add an additional confirmation of data integrity,
acting as further data validation across multiple sites. Al-
though, some level of missing data in trials is to be ex-
pected [29] and as we have shown previously, routine
data have the ability to identify some missing trial events
[30]. The above methods aim to enhance data quality
and reduce missingness.
We further validated these data and showed that these
routine data derived events could be used to perform
analyses such as survival analysis. The radiotherapy and
cystectomy survival statistics are comparable to
Table 4 Direct implications of this study to BladderPath
Outcome Database Implication from validation
Surgery to bladder - Hospital Episode Statistics (HES) - Historically high quality
- HES data alone sufficient
Chemotherapy
regimens
- Hospital Episode Statistics (HES)
- Systemic Anti-Cancer Therapy (SACT)
- Historically high quality to detect regimens
- The exact date of administrations can additionally be found in the SACT data
(and clinical noting if required)
- HES data alone sufficient
Radiotherapy regimens - Hospital Episode Statistics (HES)
- National Radiotherapy Data set
(RTDS)
- More recent high quality (since 2014) to detect regimens
- Due to the validation of the radiotherapy LINAC data, the RTDS will be used
to supplement missing events
Cystoscopy - Hospital Episode Statistics (HES)
- Diagnostic Imaging Data set (DID)
- Recent high quality (since 2016)
- Consistent high quality TURBT coding
- Historically lower quality of flexible cystoscopy coding
- Prior to trial data confidence, a database query process may be necessary
(check flag = if no flexible cystoscopy is identified prior to TURBT)
- To confirm identification of subsequent surveillance flexible cystoscopy events,
the DID will be used as a supplement
BCG regimens - Hospital Episode Statistics (HES)
- Systemic Anti-Cancer Therapy (SACT)
- More recent high quality (since 2013)
- SACT data will supplement missing administration details
Censor - Hospital Episode Statistics (HES) - Data quality historically high, but reduced recently (post-2016)
- Therefore, upon query at site, the most recent event in the clinical noting
should be confirmed
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published clinical trial results [31] and national datasets
respectively [32], further establishing the utility of both
the RTDS and HES for the trial and establishing data in-
tegrity. During the RTD analysis, HRs were also con-
structed at 5 years and to the end of the study period
(90 months) (Additional file 4). Comparison with clinical
trial results should be interpreted with caution due to
the non-comparable, non-randomised case-mix in our
patient cohorts; likewise, comparisons cannot be drawn
between radiotherapy and cystectomy outcomes due to
heterogeneity.
The algorithm is designed to capture as many events
as possible, requiring an exceptionally high sensitivity.
Therefore, additional codes are identified for unrelated
procedures (marked in Additional file 1) that may have
been incorrectly coded. For this reason, a lower PPV was
acceptable, although, a lower PPV will result in greater
burden on site staff validating false positive events, so a
balanced approach is required. It is not possible to cal-
culate the specificity or the negative predictive value as
the number of true negatives is not known; we did not
have access to a reference identifying patients that did
not have events. However, as each event will be queried
and confirmed before incorporation into the trial data-
base, by definition the trial event specificity will be
100%. For treatments with regimens (radiotherapy,
chemotherapy and BCG), it is only necessary to flag one
instance of administration per regimen to identify these
outcomes, as further targeted details can be extracted
from the clinical noting. Hence, we have shown the pri-
mary outcome for the intermediate stage of BladderPath
(time to correct treatment for all possible MIBC pa-
tients) can be feasibly identified in routine data.
Limitations of this feasibility study include single site
analysis, except for the cystectomy survival analysis
where patients from two hospital sites were analysed.
Implications of these include, coding inconsistencies, if
any, and missed events. As shown, the ability of the HID
data to replicate results using national datasets [32], sug-
gests that our sample may be representative of multiple
sites. Lack of data from other hospitals also resulted in
missing Charlson scores, as inpatient admissions oc-
curred at different sites to the radiotherapy. Although a
limitation for this paper, as discussed above, we do not
envisage a similar issue in the BladderPath trial, as we
will have data access across all English sites.
Another data limitation involves the lack of clinical/
pathological event level data in the HID, which has im-
plications to the interpretation of the survival analysis,
limiting the statistical control of the heterogeneity in the
comparisons. The strongest predictors of bladder cancer
survival include, but are not limited to, pathological pat-
terns (tumour grade, stage and lymph node involve-
ment), histologic patterns (lymphovascular invasion),
demographic and epidemiological characteristics
(gender, age) and clinical characteristics (neutrophil-
lymphocyte-ratio) [33]. Further predictors include pre-
operative (neoadjuvant) chemotherapy [34], Charlson
score [35] and soft tissue surgical margins [36] (Table 5).
Of these, gender, age, Charlson score and preoperative
neoadjuvant chemotherapy are identifiable in adminis-
trative data and as such were analysed in this analysis.
The remaining variables were not present in the HID,
but the majority can be collected using cancer registries
(Table 5). Prior to performing survival analysis within a
trial setting, all required variables should be validated for
completeness and accuracy.
In addition to a lack of fields at event level, routine
data can be limited at patient level; HES are collected
for NHS patients and not for private care; thus, these
events would be missed. Many datasets are also re-
stricted by location; HES are only collected for
England. However, there are alternatives but the prac-
tical burden (performing the processes mentioned
above) will increase upon acquisition of multiple data
sources. However, in the absence of non-English data,
the BladderPath framework ensures that follow-up
can continue using clinical noting. This has been
tested at multiple sites within BladderPath and is
feasible; this can be seen in the excellent CRF data
completion rates. In addition, the ability to query en-
sures that unavailable data variables (for example,
missing or limited by location) can be identified. Prior
to other trials utilising this method, it is vital to as-
sess if both the events and the cohort of interest are
both available within these data.
Table 5 The strongest predictors of bladder cancer survival and
whether these variables can be theoretically identified from






Lymphovascular invasion ✗ ?
Tumour stage and grade ✗ ✓
Lymph node involvement ? ✓
Neoadjuvant chemotherapya ✓ ✓
Charlson scorea ✓ ✗
Surgical margins ✗ ✓
aUsed in survival analyses. Administrative classified as HID (HES), RTDS, SACT;
registry classified as cancer registration (not including individualised cancer
registries) ✓ = theoretically collected, ✗ = not collected, ? = not explicitly
collected (e.g. histology coded and free text field available, but
lymphovascular invasion not collected individually, secondary lymph node
involvement can be coded in diagnosis fields using ICD coding, but
not obligatory)
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Although the often arbitrary value of a reference
standard has been frequently debated [37, 38], limita-
tions were identified with regards to the reference data.
Manually reviewing clinical noting can miss events oc-
curring in other hospitals and inaccurate initial record-
ing may also lead to inaccurate data [39], resulting in
inaccurate measures of sensitivity. Additional reviewers
of the reference sources were unavailable. However, the
data analysts had extensive experience of these extrac-
tion processes and datasets. In addition, clinical guid-
ance was sought (via NJ, PP and AD) where required.
Hence, errors should be minimal. In addition, the radio-
therapy RTD reference identified fractions prescribed,
not delivered (as in the HID). Although, anecdotally at
the BladderPath lead feasibility site, the prescribed and
delivered relationship is extremely close; therefore, im-
plying this would have little impact on sensitivity. This
seems a reasonable assumption to extend to all other
BladderPath sites, as implications of any misclassification
would increase sensitivity (if regimens thought to be
missed in the HID, were never delivered (only prescribed
in the RTD), the number of false negatives would
reduce).
Routine data-based follow-up aims to reduce costs
compared to standard data collection techniques. How-
ever, if the costs are too high to receive frequent datasets
from providers, these techniques become redundant.
This schema is novel and therefore the data providers
are keen to make this affordable.
There are also regulatory considerations. Hence, appli-
cations require continual communication with providers,
ideally during trial set-up. For example, consent forms
need to be designed to enable data access. Methods for
optimum BladderPath data security and privacy are be-
ing discussed, including how these data will be sent,
where these data will be analysed, stored and then kept
(retention). Retention is essential for audit purposes and
trials have to make agreements with providers.
The study aimed to identify the scope of using routine
data solely for follow-up and if possible, to design a frame-
work. The next stage is to acquire these data, validate the
framework within the trial and validate events across mul-
tiple sites. We identified the following practical consider-
ations when utilising routine data for data collection;
missingness (erroneous or occurring outside of the NHS
or England), accuracy, outcome availability, timeliness,
costs and regulatory considerations such as privacy, secur-
ity, consent and data retention. Despite these, BladderPath
has confirmed the feasibility of this approach. Liaising
with data providers throughout the trial set-up period is
essential and helps minimise these issues.
Potential strengths of this framework include higher
quality data (than if human reported), economic benefits
(funds could be redistributed elsewhere), rapid updatable
datasets, reduced burden on site staff (targeted data
queries and semi-prepopulated CRFs) improving effi-
ciency, traceable data changes (aiding audit trails), real-
time data monitoring (dashboarding) and contact-free
follow-up. These aim to be tested within BladderPath.
There are well known concerns with using routine data
to conduct clinical trials [24]. However, we believe this
trial design mitigates these concerns by using multiple
datasets to capture events and cross-correlating out-
comes with targeted data queries at site.
Conclusion
Although clinical trials have used routine data to supple-
ment or verify data collection for many decades [16–18],
to our knowledge, we believe there is limited evidence of
RCTs using routine data as the primary method of pa-
tient follow-up. Furthermore, we know of no RCTs
which use this technique in an oncology setting in the
United Kingdom. We therefore set out, and have shown,
the feasibility of this approach for use in a multi-centre
study. It is possible that for the foreseeable future there
will be reduced face-to-face clinical follow-up due to
COVID-19. Hence, a framework such as this may facili-
tate oncology research during these times.
Limitations of this approach are predominantly due to
data quality in the routine data repositories. However,
we have shown that, over time, data quality has im-
proved. So, whilst routine data are not yet of high
enough quality to be used as a sole definitive event
marker, trials can undertake an additional querying
framework such as the one which we have outlined
above. Hence, we believe that the BladderPath study
may create a paradigm shift away from traditional trial
frameworks, resulting in cheaper, less resource intensive
clinical trials; despite the requirement for bespoke vali-
dated algorithms.
Supplementary Information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s40814-020-00713-y.
Additional file 1. Coding. Description of data: Codes identified by the
algorithm to detect events and outcomes
Additional file 2. Sensitivity by event. Description of data: Total events
identified in the reference data, compared to the number identified in
the routine data, split by event
Additional file 3. Sensitivity by year. Description of data: Total events in
the analysis, identified in the reference data and the routine data, by year
Additional file 4. Hazard ratios. Description of data: Hazard ratios
constructed at five and six years of follow-up, for radiotherapy outcomes.
The hazard ratio using all available data (90 months), can also be seen.
Abbreviations
CRF: Case report form; NHS: National Health Service; RCT: Randomised
controlled trial; HES: Hospital episode statistics; HID: Hospital interactions
data; RTD: Radiotherapy data; UHB QEH: University Hospitals Birmingham
Queen Elizabeth Hospital; Charlson score: Charlson Comorbidity Index score;
Mintz et al. Pilot and Feasibility Studies           (2020) 6:165 Page 10 of 12
NIHR: National Institute for Health Research; MRI: Magnetic resonance
imaging; BC2001: Bladder Cancer 2001; HR: Hazard ratio; CI: Confidence
interval; PPV: Positive predictive value; BCG: Bacillus Calmette-Guérin;
TURBT: Transurethral resection of bladder tumour; MIBC: Muscle invasive
bladder cancer; LINAC: Linear accelerator; ICD: International classification of
diseases; OPCS: Classification of Interventions and Procedures;
RTDS: Radiotherapy data set; SACT: Systemic anti-cancer therapy;
DID: Diagnostic imaging data set
Acknowledgements
The University Hospitals Birmingham Queen Elizabeth Hospital informatics
team (AD, AJ) for extracting the local hospital service data and the ONS data
and the hospital team for extracting the radiotherapy LINAC data for
analysis. Also, Manushri Jain for further populating the reference surgical
cohort data.
Authors’ contributions
HM (lead author) undertook the event validation and wrote the manuscript.
AD extracted the routine hospital interactions data, undertook the outcome
validation and read and approved the final manuscript. PP (corresponding
author) created and provided the surgical reference data, contributed to
study design, and read edited and approved the final manuscript. HP and NJ
(chief investigator) contributed to study design and read, edited and
approved the final manuscript. Further authors AJ, AH, AP, RB all read,
commented/revised and approved the final manuscript.
Funding
PhD studentship awarded by Warwick Medical School funding the PhD of
HM.
Availability of data and materials
These data that support the findings of this study are available from
University Hospitals Birmingham, but restrictions apply to the availability of
these data, which were used under license for the current study. Due to
ethical and legal reasons, these data cannot be made publicly available, as
public availability would compromise patient confidentiality.
Ethics approval and consent to participate
Audits were registered by the University Hospitals Birmingham Queen
Elizabeth Hospital (UHB QEH) clinical audit team and did not require




The authors declare they have no competing interests.
Author details
1Warwick Medical School, University of Warwick, Coventry CV4 7AL, UK.
2University Hospitals Birmingham NHS Foundation Trust, Edgbaston,
Birmingham B15 2GW, UK. 3Institute of Cancer and Genomic Sciences,
University of Birmingham, Edgbaston, Birmingham B15 2TT, UK. 4The Institute
of Cancer Research, 237 Fulham Road, London SW3 6JB, UK. 5The Royal
Marsden NHS foundation Trust, Fulham Road, Chelsea, London SW3 6JJ, UK.
Received: 13 August 2019 Accepted: 20 October 2020
References
1. The BladderPath trial protocol v3. https://www.birmingham.ac.uk/
Documents/college-mds/trials/crctu/BladderPath/Current/protocol/
BladderPath-Protocol-v3.0-19-Feb-2019.pdf. Accessed 05 July 2019.
2. Hospital Episode Statistics. NHS Digital. http://content.digital.nhs.uk/hes.
Accessed 12 Feb 2018.
3. National Radiotherapy Database. National Cancer Registration and Analysis
Service. http://www.ncin.org.uk/collecting_and_using_data/rtds. Accessed
23 Aug 2018.
4. Systemic Anti-Cancer Therapy dataset. National Cancer Registration and
Analysis Service. http://www.ncin.org.uk/collecting_and_using_data/data_
collection/chemotherapy. Accessed 23 Aug 2018.
5. ICD Classifications. WHO. http://www.who.int/classifications/icd/en/.
Accessed 22 June 2018.
6. The processing cycle and HES data quality. NHS Digital. https://digital.nhs.uk/
data-and-information/data-tools-and-services/data-services/hospital-episode-
statistics/the-processing-cycle-and-hes-data-quality. Accessed 13 Feb 2018.
7. Spine. NHS Digital. https://digital.nhs.uk/services/spine. Accessed 14
Nov 2018.
8. Data and Audit Project. The British Association of Urological Surgeons.
https://www.baus.org.uk/professionals/baus_business/data_audit.aspx.
Accessed 19 Oct 2018.
9. Jefferies ER, Cresswell J, McGrath JS, Miller C, Hounsome L, Fowler S, et al.
Open radical cystectomy in England: the current standard of care–an
analysis of the British Association of Urological Surgeons (BAUS) cystectomy
audit and hospital episodes statistics (HES) data. BJU Int. 2018;121(6):880–5.
10. OPCS Classification of Interventions and Procedures. National Health Service
(NHS). https://www.datadictionary.nhs.uk/web_site_content/supporting_
information/clinical_coding/opcs_classification_of_interventions_and_
procedures.asp?shownav=1. Accessed 22 June 2018.
11. Core Team R. R: a language and environment for statistical computing.
Vienna, Austria: R Foundation for Statistical Computing; 2016. https://www.
R-project.org/. Accessed 22 June 2018.
12. RStudio Team (2016). RStudio: integrated development for R. RStudio, Inc.,
Boston. http://www.rstudio.com/. Accessed 22 June 2018.
13. Main Speciality Code. NHS Digital. https://www.datadictionary.nhs.uk/
data_dictionary/attributes/m/main_specialty_code_de.asp. Accessed 22
Aug 2018.
14. StataCorp. Stata statistical software: release 15. College Station: StataCorp
LLC.; 2017.
15. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying
prognostic comorbidity in longitudinal studies: development and validation.
J Chronic Dis. 1987;40(5):373–83.
16. Lewsey JD, Leyland AH, Murray GD, Boddy FA. Using routine data to
complement and enhance the results of randomised controlled trials.
Health Technol Assess. 2000;4(22):1–55.
17. Barry SJE, Dinnett E, Kean S, Gaw A, Ford I. Are routinely collected NHS
administrative records suitable for endpoint identification in clinical trials?
Evidence from the west of Scotland coronary prevention study. PLoS One.
2013;8(9):e75379.
18. Murray DW, MacLennan GS, Breeman S, Dakin HA, Johnston L, Campbell
MK, et al. A randomised controlled trial of the clinical effectiveness and
cost-effectiveness of different knee prostheses: the knee Arthroplasty trial
(KAT). Health technology assessment. Health Technol Assess. 2014;18(19):1.
19. Thorn JC, Turner E, Hounsome L, Walsh E, Down L, Donovan J, et al.
Validation of the hospital episode statistics outpatient dataset in England.
Value Health. 2014;7(17):A547–A8.
20. Kilburn LS, Aresu M, Banerji J, Barrett-Lee P, Ellis P, Bliss JM. Can routine data
be used to support cancer clinical trials? A historical baseline on which to
build: retrospective linkage of data from the TACT (CRUK 01/001) breast
cancer trial and the National Cancer Data Repository. Trials. 2017;18(1):561.
21. Cook JA, Collins GS. The rise of big clinical databases. Br J Surg. 2015;102(2):
e93–e101.
22. Van Staa TP, Goldacre B, Gulliford M, Cassell J, Pirmohamed M, Taweel A,
et al. Pragmatic randomised trials using routine electronic health records:
putting them to the test. Brit Med J (BMJ). 2012;344:e55.
23. Appleyard SE, Gilbert DC. Innovative solutions for clinical trial follow-up:
adding value from nationally held UK data. Clin Oncol. 2017;29(12):789–95.
24. McCowan C, Thomson E, Szmigielski CA, Kalra D, Sullivan FM, Prokosch HU,
et al. Using electronic health records to support clinical trials: a report on
stakeholder engagement for EHR4CR. Biomed Res Int. 2015. https://www.
hindawi.com/journals/bmri/2015/707891/.
25. Gulliford MC, van Staa T, McDermott L, Dregan A, McCann G, Ashworth M,
et al. Cluster randomised trial in the general practice research database: 1.
Electronic decision support to reduce antibiotic prescribing in primary care
(eCRT study). Trials. 2011;12(1):115.
26. Dregan A, van Staa T, Mcdermott L, McCann G, Ashworth M, Charlton J,
et al. Cluster randomized trial in the general practice research database: 2.
Secondary prevention after first stroke (eCRT study): study protocol for a
randomized controlled trial. Trials. 2012;13(1):181.
27. Dixon J. Payment by results—new financial flows in the NHS: the risks are
large but may be worth while because of potential gains. Brit Med J (BMJ).
2004;328(7446):969.
Mintz et al. Pilot and Feasibility Studies           (2020) 6:165 Page 11 of 12
28. Diagnostic Imaging Dataset. NHS England. https://www.england.nhs.uk/
statistics/statistical-work-areas/diagnostic-imaging-dataset/. Accessed 23
Aug 2018.
29. Ibrahim JG, Chu H, Chen MH. Missing data in clinical studies: issues and
methods. J Clin Oncol. 2012;30(26):3297.
30. Mintz HP, Evison F, Parsons HM, Sydes MR, Spears MR, Patel P, et al.
National, centralised hospital datasets can inform clinical trial outcomes in
prostate cancer: a pilot study in the STAMPEDE trial. J Clin Oncol. 2017;35(6
Supplement, abstract number 257):65.
31. James ND, Hussain SA, Hall E, Jenkins P, Tremlett J, Rawlings C, et al.
Radiotherapy with or without chemotherapy in muscle-invasive bladder
cancer. N Engl J Med. 2012;366(16):1477–88.
32. Afshar M, Goodfellow H, Jackson-Spence F, Evison F, Parkin J, Bryan RT, et al.
Centralisation of radical cystectomies for bladder cancer in England, a
decade on from the ‘improving outcomes guidance’: the case for super
centralisation. Brit J Urol (BJU) international. 2018;121(2):217–24.
33. Mari A, Campi R, Tellini R, Gandaglia G, Albisinni S, Abufaraj M, et al.
Patterns and predictors of recurrence after open radical cystectomy for
bladder cancer: a comprehensive review of the literature. World J Urol.
2018;36(2):157–70.
34. Vale C. Advanced bladder cancer meta-analysis collaboration. Neoadjuvant
chemotherapy in invasive bladder cancer: a systematic review and meta-
analysis. Lancet. 2003;361(9373):1927–34.
35. Mayr R, May M, Burger M, Martini T, Pycha A, Dechet C, et al. The Charlson
comorbidity index predicts survival after disease recurrence in patients
following radical cystectomy for urothelial carcinoma of the bladder. Urol
Int. 2014;93(3):303–10.
36. Novara G, Svatek RS, Karakiewicz PI, Skinner E, Ficarra V, Fradet Y, et al. Soft
tissue surgical margin status is a powerful predictor of outcomes after
radical cystectomy: a multicenter study of more than 4,400 patients. J Urol.
2010;183(6):2165–70.
37. Claassen JAHR. The gold standard: not a golden standard. Bri Med J (BMJ).
2005;330(7500):1121.
38. Versi E. "gold standard" is an appropriate term. Brit Med J (BMJ). 1992;
305(6846):187.
39. Sarkar S, Seshadri D. Conducting record review studies in clinical practice. J
Clin Diagn Res. 2014;8(9):JG01.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Mintz et al. Pilot and Feasibility Studies           (2020) 6:165 Page 12 of 12
